A study to evaluate a new drug called AMG 355, administered alone or in combination with another drug, Pembrolizumab, in patients with advanced cancers, to assess its safety and efficacy.

Critères de participation
Participants must be at least 18 years old and have histologically or cytologically confirmed metastatic or locally advanced solid tumors that have recurred and/or not responded to established and available therapies with known clinical benefit, or are unsuitable for these. This includes participants with non-small cell lung cancer (NSCLC), colorectal adenocarcinoma (CRC), gastric adenocarcinoma (GC), and melanoma. Patients with CRC must have microsatellite stable (MSS) disease. Participants must have an estimated life expectancy of at least 3 months, as assessed by the study physician, and an ECOG (Eastern Cooperative Oncology Group) status of 0 or 1. They must also be willing to undergo at least one biopsy. (BASEC)

Critères d'exclusion
Medical conditions or treatment histories that preclude participation in the study include, among others, untreated or symptomatic metastases in the central nervous system, prior T-cell receptor-targeted therapies that were discontinued due to immune-related side effects, known allergic reactions to antibody therapies, use of immunosuppressants, autoimmune diseases, active infections, prior organ transplants, as well as the use of certain medications that may interact with the study treatment. It is also important that patients do not participate simultaneously in another clinical trial. These criteria are designed to ensure that the study is as safe as possible for participants and that the results of the study are meaningful. (BASEC)